Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
European Journal of Cancer2022Vol. 167, pp. 70–80
Citations Over TimeTop 10% of 2022 papers
Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jesper van Breeschoten, Jan‐Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A. M. Stevense‐den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers‐Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk
Abstract
This study shows lower effectiveness of anti-PD -1 monotherapy and ipilimumab-nivolumab in AM, with lower response rates, PFS and OS than CM. This group of patients should be prioritised in the development of alternative treatment strategies.
Related Papers
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis(2020)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)
- → TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab(2024)